Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Colan Totte.Co.,Ltd. (7792.T)
Osaka, JP
Colan Totte Co., Ltd., established in Osaka, Japan, in 1997, operates as an international firm specializing in the development and global distribution of therapeutic devices under its proprietary Colantotte brand. The company's diverse product portfolio features an array of magnetic therapy items for domestic use, including specialized necklaces designed to alleviate neck and shoulder discomfort, loop-style products for arm support, various general joint supporters, performance-enhancing recovery apparel, and magnetic pillows. In addition to these physical goods, they also offer sleep-enhancing supplements. Furthermore, Colan Totte manages the Colantotte Safety System, an emergency notification service accessible via a unique card, pendant, or keychain. Their sales strategy incorporates wholesale partnerships, directly managed retail outlets, and a comprehensive online platform.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.34% | +6.30% | +4.34% | -2.40% | -6.92% | -0.54% | +15.51% | +33.61% | -12.94% | -12.94% | -12.94% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+16.4% ★ Q1'26: +36.7% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+29.6% ★ Q1'26: +57.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+13.7% Q1'26: +40.0% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+26.4% ★ Q1'26: +27.6% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+44.3% ★ Q1'26: +39.5% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+0.1% Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.01× ★ Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Sep 2021 actual |
Sep 2022 actual |
Sep 2023 actual |
|---|---|---|---|
| Revenue |
3.71B
est: 3.52B (+5.5%)
|
4.66B
est: 4.02B (+16.0%)
|
5.41B
est: 4.50B (+20.1%)
|
| EBITDA |
691.13M
est: 808.18M (-14.5%)
|
1.02B
est: 922.97M (+11.0%)
|
1.10B
est: 1.03B (+6.9%)
|
| EBIT |
620.54M
est: 754.56M (-17.8%)
|
945.57M
est: 861.74M (+9.7%)
|
1.02B
est: 964.64M (+5.6%)
|
| Net Income |
420.51M
est: 459.95M (-8.6%)
|
610.45M
est: 509.23M (+19.9%)
|
645.02M
est: 605.05M (+6.6%)
|
| SGA |
1.77B
est: 1.53B (+15.3%)
|
2.05B
est: 1.75B (+17.1%)
|
2.39B
est: 1.96B (+22.0%)
|
| EPS |
51.34
est: 50.40 (+1.9%)
|
68.37
est: 55.80 (+22.5%)
|
71.84
est: 66.30 (+8.4%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | A+ | 5/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-07 | A+ | 5/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-01 | A+ | 5/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 3/5 |
| 2026-04-30 | A+ | 5/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 3/5 |
| 2026-04-28 | A+ | 5/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 3/5 |
| 2026-04-27 | A+ | 5/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 3/5 |
| 2026-04-24 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hitoshi Morita | GM of Sales Headquarters & Director | — | male |
| Katsumi Komatsu | President & Chairman | — | male |
| Mayu Kawakami | Director of Internal Audit Office | — | female |
| Yoshiaki Isaka | Chief Financial Officer & Director | — | male |
| Yumiko Komatsu | Senior MD, Head of Marketing Headquarters & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 7792.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
